董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ivan Gergel | 男 | Independent Non-Executive Director | 58 | 4.67万美元 | 未持股 | 2019-04-10 |
| Balkrishan Gill | 男 | Independent Non-Executive Director | 54 | 6.44万美元 | 未持股 | 2019-04-10 |
| Alex Martin | 男 | Chief Executive Officer and Director | 51 | 43.59万美元 | 未持股 | 2019-04-10 |
| Marella Thorell | 女 | Chief Financial Officer, Chief Operating Officer, Company Secretary and Director | 52 | 36.50万美元 | 未持股 | 2019-04-10 |
| Charles Spicer | 男 | Chairman of the Board of Director and Independent Non-Executive Director | 54 | 8.68万美元 | 未持股 | 2019-04-10 |
| Joseph William Birkett | 男 | Independent Non-Executive Director | 71 | 5.27万美元 | 未持股 | 2019-04-10 |
| Sanford Zweifach | 男 | Independent Non-Executive Director | 63 | 4.67万美元 | 未持股 | 2019-04-10 |
| Sanford Zweifach | 男 | Independent Non-Executive Director | 63 | 4.67万美元 | 未持股 | 2019-04-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alex Martin | 男 | Chief Executive Officer and Director | 51 | 43.59万美元 | 未持股 | 2019-04-10 |
| Marella Thorell | 女 | Chief Financial Officer, Chief Operating Officer, Company Secretary and Director | 52 | 36.50万美元 | 未持股 | 2019-04-10 |
董事简历
中英对照 | 中文 | 英文- Ivan Gergel
-
Ivan Gergel自2018年3月起担任制药投资公司New Rhein梦百合Investors LLC的管理合伙人兼首席医疗官。在此之前，从2014年5月至2017年12月，Gergel博士担任Nektar Therapeutics公司的首席医疗官。Gergel博士在制药开发领域工作了30多年。他目前任职于CoriumInternational，Inc.公司、Realm Therapeutics公司和Neuraptive Therapeutics公司的董事会。Gergel博士拥有伦敦皇家自由医院医学院（Royal Free Hospital School of Medicine）的MBBS医学博士学位和宾夕法尼亚大学沃顿商学院（Wharton School of Business）的工商管理硕士学位。
Ivan Gergel has served as Managing Partner and Chief Medical Officer of New Rhein Healthcare Investors LLC, a pharmaceutical investment company, since March 2018. Prior to that time, from May 2014 through December 2017 Dr. Gergel served as Chief Medical Officer of Nektar Therapeutics, Inc. Dr. Gergel has worked in pharmaceutical development for over thirty years. He currently serves on the boards of directors of Corium International, Inc., Realm Therapeutics, Inc. and Neuraptive Therapeutics, Inc. Dr. Gergel holds an MBBS MD from the Royal Free Hospital School of Medicine in London and an MBA from the Wharton School of Business at the University of Pennsylvania. - Ivan Gergel自2018年3月起担任制药投资公司New Rhein梦百合Investors LLC的管理合伙人兼首席医疗官。在此之前，从2014年5月至2017年12月，Gergel博士担任Nektar Therapeutics公司的首席医疗官。Gergel博士在制药开发领域工作了30多年。他目前任职于CoriumInternational，Inc.公司、Realm Therapeutics公司和Neuraptive Therapeutics公司的董事会。Gergel博士拥有伦敦皇家自由医院医学院（Royal Free Hospital School of Medicine）的MBBS医学博士学位和宾夕法尼亚大学沃顿商学院（Wharton School of Business）的工商管理硕士学位。
- Ivan Gergel has served as Managing Partner and Chief Medical Officer of New Rhein Healthcare Investors LLC, a pharmaceutical investment company, since March 2018. Prior to that time, from May 2014 through December 2017 Dr. Gergel served as Chief Medical Officer of Nektar Therapeutics, Inc. Dr. Gergel has worked in pharmaceutical development for over thirty years. He currently serves on the boards of directors of Corium International, Inc., Realm Therapeutics, Inc. and Neuraptive Therapeutics, Inc. Dr. Gergel holds an MBBS MD from the Royal Free Hospital School of Medicine in London and an MBA from the Wharton School of Business at the University of Pennsylvania.
- Balkrishan Gill
-
Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD. - Balkrishan Gill自2017年7月以来一直担任我们的董事会成员。他是Evelo Biosciences公司的总裁、首席执行官和董事会成员（2015年6月以来）。自2015年以来，吉尔博士还曾担任Flagship Pioneural（一家创新企业，构思，创建，资源和发展一流的生命科学公司）的风险合伙人。从2016年到2019年，吉尔博士担任Realm Therapeutics plc的董事会成员。吉尔博士在伦敦国王学院（King&8217；s College）获得博士学位，并在INSEAD获得工商管理硕士学位。
- Balkrishan Gill,is the Executive Chairman of Serina Therapeutics since 2024. Dr. Gill was the CEO of Evelo Biosciences from 2015 to 2023. During the same period Dr. Gill was a special advisor and senior partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King's College, London and his MBA from INSEAD.
- Alex Martin
-
Alex Martin于2015年6月加入Realm Therapeutics，担任首席执行官兼执行董事，此前曾担任Affectis Pharmaceuticals AG的首席执行官、Intercept Pharmaceuticals NASDAQ:ICPT的首席运营官和Bioxell S.p.A的首席财务官，他的职业生涯始于任职SmithKline Beecham Pharmaceuticals公司，随后加入Novartis公司，担任Vice President，负责全球业务开发和许可。任职Realm公司之前，Martin先生曾担任Moksha8Pharmaceuticals Inc.的总裁，这是一家领先的拉丁美洲专业制药公司。Martin先生持有Cornell University的文学学士学位和Harvard的工商管理硕士学位。
Alex Martin,has served as a director of the Company since July 2019 and is currently the Chairman of Veralox Therapeutics, the Chairman of Invaria Biotherapeutics and Chief Executive Officer of Abcuro, a clinical stage biopharmaceutical company targeting cytotoxic T cells in autoimmune diseases. Mr. Martin brings more than 25 years of experience in senior executive roles in the life science industry, with a focus on business development, operations and raising capital. Previously, Mr. Martin served as Chief Executive Officer at Palladio Biosciences which was acquired by Centessa Pharmaceuticals, and prior to that he was Chief Executive Officer of Realm Therapeutics until acquired by ESSA. In his career he has served as Chief Executive Officer of Affectis Pharmaceuticals, President of moksha8, Chief Operating Officer of Intercept Pharmaceuticals and Chief Finance Officer at Bioxell. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and strategic product development, and later joined Novartis as Vice President, Global Business Development & Licensing.Mr. Martin is a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship and financing. Mr. Martin holds a B.A. from Cornell University and an M.B.A. from Harvard. - Alex Martin于2015年6月加入Realm Therapeutics，担任首席执行官兼执行董事，此前曾担任Affectis Pharmaceuticals AG的首席执行官、Intercept Pharmaceuticals NASDAQ:ICPT的首席运营官和Bioxell S.p.A的首席财务官，他的职业生涯始于任职SmithKline Beecham Pharmaceuticals公司，随后加入Novartis公司，担任Vice President，负责全球业务开发和许可。任职Realm公司之前，Martin先生曾担任Moksha8Pharmaceuticals Inc.的总裁，这是一家领先的拉丁美洲专业制药公司。Martin先生持有Cornell University的文学学士学位和Harvard的工商管理硕士学位。
- Alex Martin,has served as a director of the Company since July 2019 and is currently the Chairman of Veralox Therapeutics, the Chairman of Invaria Biotherapeutics and Chief Executive Officer of Abcuro, a clinical stage biopharmaceutical company targeting cytotoxic T cells in autoimmune diseases. Mr. Martin brings more than 25 years of experience in senior executive roles in the life science industry, with a focus on business development, operations and raising capital. Previously, Mr. Martin served as Chief Executive Officer at Palladio Biosciences which was acquired by Centessa Pharmaceuticals, and prior to that he was Chief Executive Officer of Realm Therapeutics until acquired by ESSA. In his career he has served as Chief Executive Officer of Affectis Pharmaceuticals, President of moksha8, Chief Operating Officer of Intercept Pharmaceuticals and Chief Finance Officer at Bioxell. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and strategic product development, and later joined Novartis as Vice President, Global Business Development & Licensing.Mr. Martin is a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship and financing. Mr. Martin holds a B.A. from Cornell University and an M.B.A. from Harvard.
- Marella Thorell
-
暂无中文简介
Marella Thorell was appointed Chief Financial Officer and Executive Director in March 2013 and was appointed Chief Operating Officer in October 2014. Previously, she was a key member of the Realm Therapeutics senior leadership team, and has been Company Secretary since October 2011. She offers more than 25 years of experience in finance, operations, and human resources. Previously, she was the President of Thorell Consulting, a business consulting firm. Ms. Thorell worked at Campbell Soup Company NYSE: CPB, where she held a number of financial and management roles. She began her career and earned her CPA accounting qualification with Ernst & Young LLP. Ms. Thorell holds a BS in Business from Lehigh University. -
暂无中文简介
- Marella Thorell was appointed Chief Financial Officer and Executive Director in March 2013 and was appointed Chief Operating Officer in October 2014. Previously, she was a key member of the Realm Therapeutics senior leadership team, and has been Company Secretary since October 2011. She offers more than 25 years of experience in finance, operations, and human resources. Previously, she was the President of Thorell Consulting, a business consulting firm. Ms. Thorell worked at Campbell Soup Company NYSE: CPB, where she held a number of financial and management roles. She began her career and earned her CPA accounting qualification with Ernst & Young LLP. Ms. Thorell holds a BS in Business from Lehigh University.
- Charles Spicer
-
暂无中文简介
Charles Spicer joined Realm Therapeutics in June 2013 as an Independent Non-Executive Director and was named Non-Executive Chairman in June 2014. He has more than 20 years of experience working within the healthcare sector and specifically medtech and life sciences segments. Mr. Spicer is a Non-Executive Chairman of IXICO plc LSE: IXI, Creo Medical Group plc LSE: CREO and 11 Health & Technologies Limited and chairs a U.K. Department of Health Invention for Innovation (i4i) Funding Panel. Mr. Spicer has also served as a Non-Executive of Aircraft Medical Limited and Stanmore Implants. Previously he was Chief Executive of MDY Healthcare plc, an AIM-quoted strategic investment company focused on medtech, and prior to that head of healthcare at Numis Securities and Nomura International. Mr. Spicer was awarded an MA in history from Cambridge University and a PhD from the University of London. -
暂无中文简介
- Charles Spicer joined Realm Therapeutics in June 2013 as an Independent Non-Executive Director and was named Non-Executive Chairman in June 2014. He has more than 20 years of experience working within the healthcare sector and specifically medtech and life sciences segments. Mr. Spicer is a Non-Executive Chairman of IXICO plc LSE: IXI, Creo Medical Group plc LSE: CREO and 11 Health & Technologies Limited and chairs a U.K. Department of Health Invention for Innovation (i4i) Funding Panel. Mr. Spicer has also served as a Non-Executive of Aircraft Medical Limited and Stanmore Implants. Previously he was Chief Executive of MDY Healthcare plc, an AIM-quoted strategic investment company focused on medtech, and prior to that head of healthcare at Numis Securities and Nomura International. Mr. Spicer was awarded an MA in history from Cambridge University and a PhD from the University of London.
- Joseph William Birkett
-
暂无中文简介
Joseph William Birkett joined Realm Therapeutics in 1999 as an Independent Non-Executive Director and currently serves as Senior Independent Non-Executive Director and as Chairman of the Audit Committee. Mr. Birkett is an independent consultant and investor who has served on the board of a wide range of companies, both public and private, throughout his career. Following receipt of a BSc in Economics from Sheffield University, he qualified as an FCA with Touche Ross now Deloitte & Touche LLP before pursuing a career in finance, global investment banking, and private equity. -
暂无中文简介
- Joseph William Birkett joined Realm Therapeutics in 1999 as an Independent Non-Executive Director and currently serves as Senior Independent Non-Executive Director and as Chairman of the Audit Committee. Mr. Birkett is an independent consultant and investor who has served on the board of a wide range of companies, both public and private, throughout his career. Following receipt of a BSc in Economics from Sheffield University, he qualified as an FCA with Touche Ross now Deloitte & Touche LLP before pursuing a career in finance, global investment banking, and private equity.
- Sanford Zweifach
-
暂无中文简介
Sanford Zweifach joined Realm Therapeutics in December 2017 as an Independent Non-Executive Director and serves on the Audit Committee. Mr. Zweifach has over 25 years’ experience in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising. He is the Founder and Chief Executive Officer of Nuvelution Pharma, Inc. Previously, Mr. Zweifach was the founder and CEO of Ascendancy Healthcare, Inc. He has also been a Partner at Reedland Capital Partners, CEO of Pathways Diagnostics, Managing Director / CFO of Bay City Capital, and President and CFO of Epoch Biosciences, which was acquired by Nanogen. He currently serves as the Chairman of Lyric Pharmaceuticals Inc. and IMIDomics SL. He received his BA in Biology from UC San Diego and an MS in Human Physiology from UC Davis. -
暂无中文简介
- Sanford Zweifach joined Realm Therapeutics in December 2017 as an Independent Non-Executive Director and serves on the Audit Committee. Mr. Zweifach has over 25 years’ experience in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising. He is the Founder and Chief Executive Officer of Nuvelution Pharma, Inc. Previously, Mr. Zweifach was the founder and CEO of Ascendancy Healthcare, Inc. He has also been a Partner at Reedland Capital Partners, CEO of Pathways Diagnostics, Managing Director / CFO of Bay City Capital, and President and CFO of Epoch Biosciences, which was acquired by Nanogen. He currently serves as the Chairman of Lyric Pharmaceuticals Inc. and IMIDomics SL. He received his BA in Biology from UC San Diego and an MS in Human Physiology from UC Davis.
- Sanford Zweifach
-
Sanford Zweifach自2019年7月起担任公司董事。他目前是Medicxi的风险合伙人。他曾是Nuvelution Pharma，Inc.的联合创始人兼首席执行官。此前，Zweifach先生是Ascendancy梦百合，Inc.的联合创始人兼首席执行官。他也曾一直担任Reedland Capital Partners公司的合伙人、Pathways Diagnostics公司的首席执行官、Bay City Capital公司的董事总经理兼首席财务官，以及Epoch Biosciences公司（被NanoGen公司收购）的总裁兼首席财务官。Sandy现任Palladio Biosciences，Inc.董事长、Janpix，Inc.执行董事长、Imidomics SL董事长和Compugen，Inc.非执行董事会成员。纳斯达克股票代码:CGEN。他也是Syndexis公司的董事会成员。他在加州大学圣地亚哥分校（UC San Diego）获得生物学学士学位，在加州大学戴维斯分校（UC Davis）获得人体生理学MS。
Sanford Zweifach,has served as a director of the Company since July 2019. Mr. Zweifach is the Acting President and CBO of IMIDomics, Inc. He is also a Non-Executive Board Member of Compugen, Inc., Chair of Carisma Therapeutics, Inc. and Executive Chair of Kaerus Biosciences, Ltd. In Mr. Zweifach's 30 years in the biotech industry he has sat on numerous other public and private boards. Mr. Zweifach was the Co-Founder and Chief Executive Officer of Nuvelution Pharma, Inc., the Co-founder and CEO of Ascendancy Healthcare, Inc., and a Partner at Reedland Capital Partners. Previously, Mr. Zweifach served as CEO of Pathways Diagnostics, Managing Director and CFO of Bay City Capital and President and CFO of Epoch Biosciences, which was acquired by Nanogen. Mr. Zweifach received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis. - Sanford Zweifach自2019年7月起担任公司董事。他目前是Medicxi的风险合伙人。他曾是Nuvelution Pharma，Inc.的联合创始人兼首席执行官。此前，Zweifach先生是Ascendancy梦百合，Inc.的联合创始人兼首席执行官。他也曾一直担任Reedland Capital Partners公司的合伙人、Pathways Diagnostics公司的首席执行官、Bay City Capital公司的董事总经理兼首席财务官，以及Epoch Biosciences公司（被NanoGen公司收购）的总裁兼首席财务官。Sandy现任Palladio Biosciences，Inc.董事长、Janpix，Inc.执行董事长、Imidomics SL董事长和Compugen，Inc.非执行董事会成员。纳斯达克股票代码:CGEN。他也是Syndexis公司的董事会成员。他在加州大学圣地亚哥分校（UC San Diego）获得生物学学士学位，在加州大学戴维斯分校（UC Davis）获得人体生理学MS。
- Sanford Zweifach,has served as a director of the Company since July 2019. Mr. Zweifach is the Acting President and CBO of IMIDomics, Inc. He is also a Non-Executive Board Member of Compugen, Inc., Chair of Carisma Therapeutics, Inc. and Executive Chair of Kaerus Biosciences, Ltd. In Mr. Zweifach's 30 years in the biotech industry he has sat on numerous other public and private boards. Mr. Zweifach was the Co-Founder and Chief Executive Officer of Nuvelution Pharma, Inc., the Co-founder and CEO of Ascendancy Healthcare, Inc., and a Partner at Reedland Capital Partners. Previously, Mr. Zweifach served as CEO of Pathways Diagnostics, Managing Director and CFO of Bay City Capital and President and CFO of Epoch Biosciences, which was acquired by Nanogen. Mr. Zweifach received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.
高管简历
中英对照 | 中文 | 英文- Alex Martin
Alex Martin于2015年6月加入Realm Therapeutics，担任首席执行官兼执行董事，此前曾担任Affectis Pharmaceuticals AG的首席执行官、Intercept Pharmaceuticals NASDAQ:ICPT的首席运营官和Bioxell S.p.A的首席财务官，他的职业生涯始于任职SmithKline Beecham Pharmaceuticals公司，随后加入Novartis公司，担任Vice President，负责全球业务开发和许可。任职Realm公司之前，Martin先生曾担任Moksha8Pharmaceuticals Inc.的总裁，这是一家领先的拉丁美洲专业制药公司。Martin先生持有Cornell University的文学学士学位和Harvard的工商管理硕士学位。
Alex Martin,has served as a director of the Company since July 2019 and is currently the Chairman of Veralox Therapeutics, the Chairman of Invaria Biotherapeutics and Chief Executive Officer of Abcuro, a clinical stage biopharmaceutical company targeting cytotoxic T cells in autoimmune diseases. Mr. Martin brings more than 25 years of experience in senior executive roles in the life science industry, with a focus on business development, operations and raising capital. Previously, Mr. Martin served as Chief Executive Officer at Palladio Biosciences which was acquired by Centessa Pharmaceuticals, and prior to that he was Chief Executive Officer of Realm Therapeutics until acquired by ESSA. In his career he has served as Chief Executive Officer of Affectis Pharmaceuticals, President of moksha8, Chief Operating Officer of Intercept Pharmaceuticals and Chief Finance Officer at Bioxell. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and strategic product development, and later joined Novartis as Vice President, Global Business Development & Licensing.Mr. Martin is a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship and financing. Mr. Martin holds a B.A. from Cornell University and an M.B.A. from Harvard.- Alex Martin于2015年6月加入Realm Therapeutics，担任首席执行官兼执行董事，此前曾担任Affectis Pharmaceuticals AG的首席执行官、Intercept Pharmaceuticals NASDAQ:ICPT的首席运营官和Bioxell S.p.A的首席财务官，他的职业生涯始于任职SmithKline Beecham Pharmaceuticals公司，随后加入Novartis公司，担任Vice President，负责全球业务开发和许可。任职Realm公司之前，Martin先生曾担任Moksha8Pharmaceuticals Inc.的总裁，这是一家领先的拉丁美洲专业制药公司。Martin先生持有Cornell University的文学学士学位和Harvard的工商管理硕士学位。
- Alex Martin,has served as a director of the Company since July 2019 and is currently the Chairman of Veralox Therapeutics, the Chairman of Invaria Biotherapeutics and Chief Executive Officer of Abcuro, a clinical stage biopharmaceutical company targeting cytotoxic T cells in autoimmune diseases. Mr. Martin brings more than 25 years of experience in senior executive roles in the life science industry, with a focus on business development, operations and raising capital. Previously, Mr. Martin served as Chief Executive Officer at Palladio Biosciences which was acquired by Centessa Pharmaceuticals, and prior to that he was Chief Executive Officer of Realm Therapeutics until acquired by ESSA. In his career he has served as Chief Executive Officer of Affectis Pharmaceuticals, President of moksha8, Chief Operating Officer of Intercept Pharmaceuticals and Chief Finance Officer at Bioxell. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and strategic product development, and later joined Novartis as Vice President, Global Business Development & Licensing.Mr. Martin is a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship and financing. Mr. Martin holds a B.A. from Cornell University and an M.B.A. from Harvard.
- Marella Thorell
Marella Thorell预计将担任我们的董事会成员，并在本次发行完成后担任我们的审计委员会主席。她是Palladio Biosciences公司的首席财务官。最近，Thorell女士担任Realm Therapeutics的首席财务官/首席运营官兼执行董事，该公司于2019年7月被ESSA Pharma收购，此前曾在Realm担任多个其他高级职位。Thorell女士在收购后被任命为ESSA的董事。Thorell女士曾在康宝浓汤公司工作，担任多个财务和管理职务，责任越来越大。她也曾担任执行顾问，专注于财务和人力资本项目。她的职业生涯始于任职Ernst&Young，LLP，并获得注册会计师资格。Thorell女士以优异成绩获得利哈伊大学（Lehigh University）商学学士学位。
Marella Thorell,has been a member of ESSA's board since 2019 and was Chief Financial Officer of Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects through December 2023. Ms. Thorell has more than 25 years of experience in finance and operations. Prior to Evelo, Ms. Thorell served as Chief Accounting Officer at Centessa Pharmaceuticals plc (Nasdaq: CNTA) where she led the establishment of Centessa's finance operations, its public company readiness activities in connection with its initial public offering and oversaw finance and accounting operations. Prior to that, she was the Chief Financial Officer of Palladio Biosciences Inc., before its acquisition by Centessa. Previously, Ms. Thorell served as Chief Financial Officer, Chief Operating Officer and Executive Director of Realm Therapeutics plc ("Realm") until the company was acquired by ESSA in 2019. At Realm, Ms. Thorell was responsible for in-licensing and out-licensing assets, and capital strategy to fund growth and clinical development. Ms. Thorell began her career and earned her CPA at Ernst & Young, LLP. Subsequently, she worked for Campbell Soup Company in finance and operational roles of increasing responsibility and served as an executive consultant focusing on financial and human capital projects. Ms. Thorell earned a B.S.in Business from Lehigh University, magna cum laude. Ms. Thorell served as a Director of Vallon Pharmaceuticals, including as Board Chair and Audit Committee Chair at different points during her tenure, from February 2021 until its merger with GRI Bio, Inc. in April 2023.- Marella Thorell预计将担任我们的董事会成员，并在本次发行完成后担任我们的审计委员会主席。她是Palladio Biosciences公司的首席财务官。最近，Thorell女士担任Realm Therapeutics的首席财务官/首席运营官兼执行董事，该公司于2019年7月被ESSA Pharma收购，此前曾在Realm担任多个其他高级职位。Thorell女士在收购后被任命为ESSA的董事。Thorell女士曾在康宝浓汤公司工作，担任多个财务和管理职务，责任越来越大。她也曾担任执行顾问，专注于财务和人力资本项目。她的职业生涯始于任职Ernst&Young，LLP，并获得注册会计师资格。Thorell女士以优异成绩获得利哈伊大学（Lehigh University）商学学士学位。
- Marella Thorell,has been a member of ESSA's board since 2019 and was Chief Financial Officer of Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects through December 2023. Ms. Thorell has more than 25 years of experience in finance and operations. Prior to Evelo, Ms. Thorell served as Chief Accounting Officer at Centessa Pharmaceuticals plc (Nasdaq: CNTA) where she led the establishment of Centessa's finance operations, its public company readiness activities in connection with its initial public offering and oversaw finance and accounting operations. Prior to that, she was the Chief Financial Officer of Palladio Biosciences Inc., before its acquisition by Centessa. Previously, Ms. Thorell served as Chief Financial Officer, Chief Operating Officer and Executive Director of Realm Therapeutics plc ("Realm") until the company was acquired by ESSA in 2019. At Realm, Ms. Thorell was responsible for in-licensing and out-licensing assets, and capital strategy to fund growth and clinical development. Ms. Thorell began her career and earned her CPA at Ernst & Young, LLP. Subsequently, she worked for Campbell Soup Company in finance and operational roles of increasing responsibility and served as an executive consultant focusing on financial and human capital projects. Ms. Thorell earned a B.S.in Business from Lehigh University, magna cum laude. Ms. Thorell served as a Director of Vallon Pharmaceuticals, including as Board Chair and Audit Committee Chair at different points during her tenure, from February 2021 until its merger with GRI Bio, Inc. in April 2023.